‌

US Patent 9963504 Anti-CXCL13 antibodies and methods of using the same

Patent 9963504 was granted and assigned to Vaccinex, Inc on May, 2018 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent attributes

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Mark Paris0

Ernest S. Smith0

Ekaterina Klimatcheva0

Date of Patent

May 8, 2018

Patent Application Number

13820278

Date Filed

September 1, 2011

Patent Citations Received

US Patent 11702470 Use of CXCL13 binding molecules to promote peripheral nerve regeneration

0

Patent Primary Examiner

Patent abstract

Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 9963504 Anti-CXCL13 antibodies and methods of using the same

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.